siRNA Nanoparticles Open a New Path for Cancer Therapy
Background and Challenges
siRNA possesses excellent efficacy for gene silencing, but it encounters numerous barriers such as rapid clearance from the bloodstream, poor membrane permeability, capture by the mononuclear phagocyte system, renal excretion, endosomal escape, and precise cell recognition. These combined obstacles have limited its clinical application.
Innovative Nanodelivery Strategies
Researchers have designed particles using a variety of nanomaterials—including lipids, polymers, inorganic substances, hybrids, and siRNA conjugates. Nanoparticles markedly increase delivery efficiency while reducing cytotoxicity and minimizing off‑target effects. Each matrix provides tailored functions to bypass barriers or promote endosomal escape.
Future Outlook and Clinical Potential
siRNA‑loaded nanoparticles have entered clinical trial phases for several cancer types, and early results demonstrate both safety and efficacy. With further design optimization and large‑scale validation, they are expected to become a more precise and less toxic therapeutic option compared with conventional chemotherapies.
siRNA, as a precise, specific, and highly effective gene-silencing therapy, has been extensively studied. Before reaching tumor cell targets, siRNA formulations must overcome multiple extracellular barriers, including clearance from the bloodstream, membrane impermeability, capture by the mononuclear phagocyte system (MPS), rapid renal excretion, endosomal escape, and precise recognition of target cells. These challenges limit siRNA's clinical application. Consequently, various modifications have been applied to siRNA to enhance transfection efficiency, while researchers continue to pursue improved siRNA-targeting delivery systems. Nanotechnology offers a rational technical approach to address siRNA delivery. Nanoparticles can increase transfection efficiency while exhibiting lower cytotoxicity and reduced off-target effects. Various matrices have been employed to construct nanoparticles for targeted therapeutic delivery. This review briefly discusses siRNA nanoparticle delivery strategies, illustrates examples of various siRNA nanodelivery systems, such as lipid nanoparticles, polymeric siRNA nanoparticles, inorganic nanoparticles, hybrid nanoparticles, and conjugate-siRNA delivery systems, and introduces clinical trials of siRNA-loaded nanoparticles for cancer treatment, which can provide valuable references for further research and clinical application of siRNA nanoparticle delivery systems.
siRNA therapy has overcome the difficulty of reaching target cells within the body. As a result, cancer patients can receive more precise and less side‑effect‑prone treatments.